{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:11Z","timestamp":1793676371202,"version":"4.5.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA046345"],"award-info":[{"award-number":["DA046345"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine the relationship between brain mu opioid receptor (MOR) availability and liver activity in opioid use disorder (OUD) patients treated with methadone (MET) or buprenorphine (BUP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      10 OUD patients, 5 treated with MET and 5 with BUP, as well as 13 healthy controls (HCs) underwent total-body PET [\n                      <jats:sup>11<\/jats:sup>\n                      C]carfentanil (CFN) imaging. MOR availability was quantified using distribution volume ratio (DVR) in key MOR-rich brain regions, and hepatic distribution volume (Vt) was used as an index of systemic tracer pharmacokinetics. Serum drug levels were measured in the OUD patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Brain MOR availability was significantly lower in the OUD groups relative to HCs (p\u2009&lt;\u20090.001), more so in BUP-treated (mean MOR difference\u2009=\u200939.9\u2009\u00b1\u200915.9%, Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      \u2009=\u20093.35) than MET-treated (mean MOR difference\u2009=\u200914.2\u2009\u00b1\u20099.9%,\n                      <jats:italic>d<\/jats:italic>\n                      \u2009=\u20091.90) patients. Central MOR availability was inversely related to serum drug levels, linearly in MET treated (R2\u2009=\u20090.83) and logarithmically in BUP-treated (R2\u2009=\u20090.96), consistent with distinct receptor occupancy dynamics. Hepatic Vt differed across groups (p\u2009&lt;\u20090.003) with levels in both OUD groups lower than in HCs (p\u2009&lt;\u20090.05). In MET-treated patients, hepatic Vt was strongly associated with brain MOR availability (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.68), and inversely associated with serum drug levels (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.63). This relationship was less pronounced in BUP-treated patients (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.30), and absent in HCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Drug-specific, brain-liver pharmacokinetic profiles were observed in OUD patients treated with MET versus BUP. While MET patients demonstrated coupling between hepatic tracer kinetics and brain receptor occupancy, BUP patients did not. These findings demonstrate that drug-specific brain-body pharmacokinetics may underscore observed clinical differences in opioid agonist effects in OUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08144-2","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:02:10Z","timestamp":1787385730000},"page":"7898-7909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Total-body [11C]carfentanil PET: Liver-brain axis in methadone vs. buprenorphine treatment"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-0594","authenticated-orcid":false,"given":"Elizabeth J.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2934-8794","authenticated-orcid":false,"given":"Corinde E.","family":"Wiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ju","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiaoju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-0450","authenticated-orcid":false,"given":"Henry R.","family":"Kranzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0732-2374","authenticated-orcid":false,"given":"Jacob G.","family":"Dubroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"8144_CR1","unstructured":"CDC. Understanding the Opioid Overdose Epidemic. U.S. Centers for Disease Control and Prevention. Accessed 2025."},{"key":"8144_CR2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/add.16081","volume":"118","author":"M Robert","year":"2023","unstructured":"Robert M, Jouanjus E, Khouri C, Fouilhe Sam-Lai N, Revol B. The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database. Addiction. 2023;118:771\u20135. https:\/\/doi.org\/10.1111\/add.16081.","journal-title":"Addiction"},{"key":"8144_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1176\/appi.ajp.20230273","volume":"180","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Blanco C. Fentanyl and Other Opioid Use Disorders: Treatment and Research Needs. Am J Psychiatry. 2023;180:410\u20137. https:\/\/doi.org\/10.1176\/appi.ajp.20230273.","journal-title":"Am J Psychiatry"},{"key":"8144_CR4","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","volume":"393","author":"C Blanco","year":"2019","unstructured":"Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393:1760\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(18)33078-2.","journal-title":"Lancet"},{"key":"8144_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","volume":"2014","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014:CD002207. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"8144_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/add.70000","volume":"120","author":"M Meyer","year":"2025","unstructured":"Meyer M, Strazdins E, Guessoum A, Westenberg JN, Appenzeller-Herzog C, Cattaneo M, et al. Relative risks of adverse effects across different opioid agonist treatments-A systematic review and meta-analysis. Addiction. 2025;120:1112\u201326. https:\/\/doi.org\/10.1111\/add.70000.","journal-title":"Addiction"},{"issue":"12","key":"8144_CR7","doi-asserted-by":"publisher","first-page":"e2551337","DOI":"10.1001\/jamanetworkopen.2025.51337","volume":"8","author":"B-A Enns","year":"2025","unstructured":"Enns B-A, Min JE, Carter A, Siebert U, Nosyk B. Population-level health benefits and harms associated with buprenorphine\/naloxone vs methadone. JAMA Netw Open. 2025;8:e2551337. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.51337.","journal-title":"JAMA Netw Open"},{"key":"8144_CR8","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","volume":"332","author":"B Nosyk","year":"2024","unstructured":"Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, et al. Buprenorphine\/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024;332:1822\u201331. https:\/\/doi.org\/10.1001\/jama.2024.16954.","journal-title":"JAMA"},{"key":"8144_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2967\/jnumed.124.269413","volume":"66","author":"JG Dubroff","year":"2025","unstructured":"Dubroff JG, Hsieh CJ, Wiers CE, Lee H, Schmitz A, Li EJ, et al. [(11)C]Carfentanil PET Whole-Body Imaging of mu-Opioid Receptors: A First in-Human Study. J Nucl Med. 2025;66:1112\u20138. https:\/\/doi.org\/10.2967\/jnumed.124.269413.","journal-title":"J Nucl Med"},{"key":"8144_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/jcbfm.1989.59","volume":"9","author":"JJ Frost","year":"1989","unstructured":"Frost JJ, Douglass KH, Mayberg HS, Dannals RF, Links JM, Wilson AA, et al. Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab. 1989;9:398\u2013409. https:\/\/doi.org\/10.1038\/jcbfm.1989.59.","journal-title":"J Cereb Blood Flow Metab"},{"key":"8144_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","volume":"61","author":"M Greenwald","year":"2007","unstructured":"Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61:101\u201310. https:\/\/doi.org\/10.1016\/j.biopsych.2006.04.043.","journal-title":"Biol Psychiatry"},{"key":"8144_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06746-2","author":"CJ Hsieh","year":"2024","unstructured":"Hsieh CJ, Hou C, Lee H, Tomita C, Schmitz A, Plakas K, et al. Total-body imaging of mu-opioid receptors with [(11)C]carfentanil in non-human primates. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-06746-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8144_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","volume":"23","author":"J Zubieta","year":"2000","unstructured":"Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000;23:326\u201334. https:\/\/doi.org\/10.1016\/S0893-133X(00)00110-X.","journal-title":"Neuropsychopharmacology"},{"key":"8144_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28:2000\u20139. https:\/\/doi.org\/10.1038\/sj.npp.1300251.","journal-title":"Neuropsychopharmacology"},{"key":"8144_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0022-3565(24)39007-X","volume":"295","author":"MA Kling","year":"2000","unstructured":"Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, et al. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295:1070\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"8144_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1124\/jpet.104.072686","volume":"312","author":"JK Melichar","year":"2005","unstructured":"Melichar JK, Hume SP, Williams TM, Daglish MR, Taylor LG, Ahmad R, et al. Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther. 2005;312:309\u201315. https:\/\/doi.org\/10.1124\/jpet.104.072686.","journal-title":"J Pharmacol Exp Ther"},{"key":"8144_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00429-014-0717-9","volume":"220","author":"E Erbs","year":"2015","unstructured":"Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, Vonesch JL, et al. A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct. 2015;220:677\u2013702. https:\/\/doi.org\/10.1007\/s00429-014-0717-9.","journal-title":"Brain Struct Funct"},{"key":"8144_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neuropharm.2013.08.028","volume":"76","author":"P Charbogne","year":"2014","unstructured":"Charbogne P, Kieffer BL, Befort K. 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology. 2014;76:204\u201317. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.028.","journal-title":"Neuropharmacology"},{"key":"8144_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/mp.2014.185","volume":"20","author":"DT Hsu","year":"2015","unstructured":"Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, et al. It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry. 2015;20:193\u2013200. https:\/\/doi.org\/10.1038\/mp.2014.185.","journal-title":"Mol Psychiatry"},{"key":"8144_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bcp.2018.02.020","volume":"153","author":"T Ahmad","year":"2018","unstructured":"Ahmad T, Valentovic MA, Rankin GO. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018;153:196\u2013204. https:\/\/doi.org\/10.1016\/j.bcp.2018.02.020.","journal-title":"Biochem Pharmacol"},{"key":"8144_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50:551\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2004.05.002.","journal-title":"Pharmacol Res"},{"key":"8144_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.toxlet.2022.07.006","volume":"367","author":"L Kong","year":"2022","unstructured":"Kong L, Walz AJ. Metabolism of the active carfentanil metabolite, 4-Piperidinecarboxylic acid, 1-(2-hydroxy-2-phenylethyl)-4-[(1-oxopropyl)phenylamino]-, methyl ester in vitro. Toxicol Lett. 2022;367:32\u20139. https:\/\/doi.org\/10.1016\/j.toxlet.2022.07.006.","journal-title":"Toxicol Lett"},{"key":"8144_CR23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/bja\/82.6.900","volume":"82","author":"Y Oda","year":"1999","unstructured":"Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth. 1999;82:900\u20133. https:\/\/doi.org\/10.1093\/bja\/82.6.900.","journal-title":"Br J Anaesth"},{"key":"8144_CR24","doi-asserted-by":"crossref","unstructured":"Diagnostic and statistical manual of mental disorders : DSM-5. American Psychiatric Publishing. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"8144_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jlcr.3513","volume":"60","author":"JE Blecha","year":"2017","unstructured":"Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta JK, DaSilva AF, et al. An updated synthesis of [(11) C]carfentanil for positron emission tomography (PET) imaging of the mu-opioid receptor. J Labelled Comp Radiopharm. 2017;60:375\u201380. https:\/\/doi.org\/10.1002\/jlcr.3513.","journal-title":"J Labelled Comp Radiopharm"},{"key":"8144_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2967\/jnumed.119.229997","volume":"61","author":"JS Karp","year":"2020","unstructured":"Karp JS, Viswanath V, Geagan MJ, Muehllehner G, Pantel AR, Parma MJ, et al. PennPET Explorer: Design and Preliminary Performance of a Whole-Body Imager. J Nucl Med. 2020;61:136\u201343. https:\/\/doi.org\/10.2967\/jnumed.119.229997.","journal-title":"J Nucl Med"},{"key":"8144_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2967\/jnumed.119.231845","volume":"61","author":"AR Pantel","year":"2020","unstructured":"Pantel AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, Muehllehner G, Parma MJ, et al. PennPET Explorer: Human Imaging on a Whole-Body Imager. J Nucl Med. 2020;61:144\u201351. https:\/\/doi.org\/10.2967\/jnumed.119.231845.","journal-title":"J Nucl Med"},{"key":"8144_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1109\/42.712135","volume":"17","author":"DL Collins","year":"1998","unstructured":"Collins DL, Zijdenbos AP, Kollokian V, Sled JG, Kabani NJ, Holmes CJ, et al. Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging. 1998;17:463\u20138. https:\/\/doi.org\/10.1109\/42.712135.","journal-title":"IEEE Trans Med Imaging"},{"key":"8144_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1006\/nimg.2001.0978","volume":"15","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273\u201389. https:\/\/doi.org\/10.1006\/nimg.2001.0978.","journal-title":"Neuroimage"},{"key":"8144_CR30","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340. https:\/\/doi.org\/10.1097\/00004647-199609000-00008.","journal-title":"J Cereb Blood Flow Metab"},{"key":"8144_CR31","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00259-008-0935-6","volume":"36","author":"J Hirvonen","year":"2009","unstructured":"Hirvonen J, Aalto S, Hagelberg N, Maksimow A, Ingman K, Oikonen V, et al. Measurement of central \u00b5-opioid receptor binding in vivo with PET and [11C] carfentanil: a test\u2013retest study in healthy subjects. Eur J Nucl Med Mol Imaging. 2009;36:275\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8144_CR32","doi-asserted-by":"crossref","unstructured":"Tierney TM, Alexander NA, Avila NL, Balbastre Y, Barnes G, Bezsudnova Y, et al. SPM 25: open source neuroimaging analysis software. J Open Source Softw. 2025;10:8103.","DOI":"10.21105\/joss.08103"},{"key":"8144_CR33","doi-asserted-by":"publisher","first-page":"175023","DOI":"10.1088\/1361-6560\/ab1f29","volume":"64","author":"Y Zuo","year":"2019","unstructured":"Zuo Y, Sarkar S, Corwin MT, Olson K, Badawi RD, Wang G. Structural and practical identifiability of dual-input kinetic modeling in dynamic PET of liver inflammation. Phys Med Biol. 2019;64:175023. https:\/\/doi.org\/10.1088\/1361-6560\/ab1f29.","journal-title":"Phys Med Biol"},{"key":"8144_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159043359477","volume":"2","author":"K Lutfy","year":"2004","unstructured":"Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2:395\u2013402. https:\/\/doi.org\/10.2174\/1570159043359477.","journal-title":"Curr Neuropharmacol"},{"key":"8144_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/10550887.2010.531672","volume":"30","author":"A Fareed","year":"2011","unstructured":"Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, Bailey SP. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis. 2011;30:27\u201338. https:\/\/doi.org\/10.1080\/10550887.2010.531672.","journal-title":"J Addict Dis"},{"key":"8144_CR36","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nrn3119","volume":"12","author":"RZ Goldstein","year":"2011","unstructured":"Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci. 2011;12:652\u201369. https:\/\/doi.org\/10.1038\/nrn3119.","journal-title":"Nat Rev Neurosci"},{"key":"8144_CR37","doi-asserted-by":"publisher","first-page":"116922","DOI":"10.1016\/j.neuroimage.2020.116922","volume":"217","author":"T Kantonen","year":"2020","unstructured":"Kantonen T, Karjalainen T, Isojarvi J, Nuutila P, Tuisku J, Rinne J, et al. Interindividual variability and lateralization of mu-opioid receptors in the human brain. Neuroimage. 2020;217:116922. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.116922.","journal-title":"Neuroimage"},{"key":"8144_CR38","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1176\/ajp.156.6.842","volume":"156","author":"JK Zubieta","year":"1999","unstructured":"Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry. 1999;156:842\u20138. https:\/\/doi.org\/10.1176\/ajp.156.6.842.","journal-title":"Am J Psychiatry"},{"key":"8144_CR39","doi-asserted-by":"publisher","first-page":"e0177785","DOI":"10.1371\/journal.pone.0177785","volume":"12","author":"R Mabrouk","year":"2017","unstructured":"Mabrouk R, Strafella AP, Knezevic D, Ghadery C, Mizrahi R, Gharehgazlou A, et al. Feasibility study of TSPO quantification with [18F]FEPPA using population-based input function. PLoS ONE. 2017;12:e0177785. https:\/\/doi.org\/10.1371\/journal.pone.0177785.","journal-title":"PLoS ONE"},{"key":"8144_CR40","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.neuroimage.2012.08.007","volume":"63","author":"P Zanotti-Fregonara","year":"2012","unstructured":"Zanotti-Fregonara P, Hines CS, Zoghbi SS, Liow J-S, Zhang Y, Pike VW, et al. Population-based input function and image-derived input function for [11C](R)-rolipram PET imaging: Methodology, validation and application to the study of major depressive disorder. Neuroimage. 2012;63:1532\u201341. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.08.007.","journal-title":"Neuroimage"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08144-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08144-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08144-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:30:00Z","timestamp":1793673000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08144-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":40,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8144"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08144-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, with all procedures approved by the University of Pennsylvania\u2019s Institutional Review Board (Penn IRB #851051) and the study was registered on clinicaltrials.gov (NCT05528848).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Was obtained from all individual participants included in this study. Prospective participants were first screened by telephone through a partial HIPAA waiver and, if eligible, were seen in person for informed consent and evaluation.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kranzler is a member of advisory boards for Altimmune, Clearmind Medicine, and Niuvera Bio; a consultant to Sobrera Pharmaceuticals, Altimmune, Lilly, Ribocure, and Boehringer Ingelheim; and the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes and company-initiated studies by Altimmune and Lilly.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}